11月27日,科伦博泰首个国产靶向TROP2(人滋养细胞表面抗原2)的抗体药物偶联物(ADC)芦康沙妥珠单抗(sac-TMT)获国家药品监督管理局(NMPA)批准于中国上市。截至当天收盘,科伦博泰(6990.HK)股价大涨超过10%。今年以来,该公司股价已经实现翻番。默沙东成为幕后“大赢家”这款最新获批的ADC药物不仅是首个在中国获批上市的国产TROP2 ADC,也是中国首个获得完全批准上市的国产...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.